Steatosis and chronic hepatitis C virus infection: Mechanisms and significance

Clinics in Liver Disease

Volumn 9, Issue 3, 2005, Pages 399-410

  Patel, Keyur ^a   Zekry, Amany ^a   McHutchison, John G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; PIOGLITAZONE; ROSIGLITAZONE;

BODY MASS; CANCER GROWTH; CANCER RISK; CHOLESTEROL METABOLISM; DIET THERAPY; DISEASE COURSE; DISEASE SEVERITY; EXERCISE; GENE EXPRESSION; GENOTYPE; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER INJURY; LIVER METABOLISM; NONHUMAN; OBESITY; PATHOGENESIS; REVIEW; RISK ASSESSMENT; STEATOSIS;

BODY MASS INDEX; FATTY LIVER; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIPID MOBILIZATION; RISK FACTORS; VIRAL PROTEINS;

EID: 22044447648     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2005.05.007     Document Type: Review

References (69)

1. J.M. Clark, F.L. Brancati, and A.M. Diehl Nonalcoholic fatty liver disease Gastroenterology 122 2002 1649 1657
2. Z.D. Goodman, and K.G. Ishak Histopathology of hepatitis C virus infection Semin Liver Dis 15 1995 70 81
3. A.J. Czaja, H.A. Carpenter, and P.J. Santrach Host- and disease-specific factors affecting steatosis in chronic hepatitis C J Hepatol 29 1998 198 206
4. S.J. Hwang, J.C. Luo, and C.W. Chu Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation J Gastroenterol Hepatol 16 2001 190 195
5. L.F. Hourigan, G.A. Macdonald, and D. Purdie Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis Hepatology 29 1999 1215 1219
6. K.Q. Hu, N.L. Kyulo, and E. Esrailian Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States J Hepatol 40 2004 147 154
7. H.M. Patton, K. Patel, and C. Behling The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients J Hepatol 40 2004 484 490
8. T. Poynard, V. Ratziu, and J. McHutchison Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C Hepatology 38 2003 75 85
9. L. Rubbia-Brandt, R. Quadri, and K. Abid Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3 J Hepatol 33 2000 106 115
10. D. Kumar, G.C. Farrell, and C. Fung Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response Hepatology 36 2002 1266 1272
11. L.E. Adinolfi, R. Utili, and A. Andreana Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C Dig Dis Sci 6 2001 1677 1683
12. J.M. Hui, A. Sud, and G.C. Farrell Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression Gastroenterology 125 2003 1695 1704
13. L. Fartoux, O. Chazouilleres, and D. Wendum Impact of steatosis on progression of fibrosis in patients with mild hepatitis C Hepatology 41 2004 82 87
14. K. Ohata, K. Hamasaki, and K. Toriyama Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection Cancer 97 2003 3036 3043
15. A. Monto, J. Alonzo, and J.J. Watson Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol Hepatology 36 2002 729 736
16. A.J. Sanyal, M.J. Contos, and R.K. Sterling Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome Am J Gastroenterol 98 2003 2064 2071
17. A.D. Clouston, J.R. Jonsson, and D.M. Purdie Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation J Hepatol 34 2001 314 320
18. P.A. Gochee, J.R. Jonsson, and A.D. Clouston Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1 J Gastroenterol Hepatol 18 2003 386 392
19. J. Westin, H. Nordlinder, and M. Lagging Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients J Hepatol 37 2002 837 842
20. L.E. Adinolfi, M. Gambardella, and A. Andreana Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity Hepatology 33 2001 1358 1364
21. L. Rubbia-Brandt, P. Fabris, and S. Paganin Steatosis affects chronic hepatitis C progression in a genotype specific way Gut 53 2004 406 412
22. F. Cholet, J.B. Nousbaum, and M. Richecoeur Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients Gastroenterol Clin Biol 28 2004 272 278
23. I.J. Hickman, A.D. Clouston, and G.A. Macdonald Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C Gut 51 2002 89 94
24. J.P. Ong, Z.M. Younossi, and C. Speer Chronic hepatitis C and superimposed nonalcoholic fatty liver disease Liver 21 2001 266 271
25. A.D. Clouston, J.R. Jonnson, and D.M. Purdie Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation J Hepatol 34 2001 314 320
26. C.P. Day, and O.F. James Steatohepatitis: a tale of two "hits"? Gastroenterology 114 1998 842 845
27. I.J. Hickman, E.E. Powell, and J.B. Prins In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy J Hepatol 39 2003 1042 1048
28. V. Ratziu, M. Munteanu, and F. Charlotte Fibrogenic impact of high serum glucose in chronic hepatitis C. LIDO Study Group J Hepatol 39 2003 1049 1055
29. A. Muzzi, G. Leandro, and L. Rubbia-Brandt Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients J Hepatol 42 2005 41 46
30. V. Paradis, G. Perlemuter, and F. Bonvoust High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis Hepatology 34 2001 738 744
31. Y. Kamada, S. Tamura, and S. Kiso Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin Gastroenterology 125 2003 1796 1807
32. L. Castera, C. Hezode, and F. Roudot-Thoraval Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies Gut 52 2003 288 292
33. J.A. Marrero, R.J. Fontana, and G.L. Su NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States Hepatology 36 2002 1349 1354
34. H.B. El-Serag Hepatocellular carcinoma and hepatitis C in the United States Hepatology 36 2002 S74 S83
35. H.B. El-Serag, T. Tran, and J.E. Everhart Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma Gastroenterology 126 2004 460 468
36. K. Moriya, K. Nakagawa, and T. Santa Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis Cancer Res 61 2001 4365 4370
37. M. Okuda, K. Li, and M.R. Beard Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein Gastroenterology 122 2002 366 375
38. T. Tsutsumi, T. Suzuki, and T. Shimoike Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity Hepatology 35 2002 937 946
39. H.M. Patton, K. Patel, and J.G. McHutchison Hepatic steatosis in chronic hepatitis C virus infection: a review of mechanisms, influence on natural history, and treatment outcomes Hepatol Rev 1 2004 23 31
40. C. Gasteyger, and A. Tremblay Metabolic impact of body fat distribution J Endocrinol Invest 25 2002 876 883
41. W. Aldhahi, and O. Hamdy Adipokines, inflammation, and the endothelium in diabetes Curr Diab Rep 3 2003 293 298
42. S.H. Mehta, F.L. Brancati, and M.S. Sulkowski Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States Ann Intern Med 133 2000 592 599
43. B.B. Kahn, and J.S. Flier Obesity and insulin resistance J Clin Invest 106 2000 473 481
44. Y. Shintani, H. Fujie, and H. Miyoshi Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance Gastroenterology 126 2004 840 848
45. L.M. Kaplan Leptin, obesity, and liver disease Gastroenterology 115 1998 997 1001
46. E. Giannini, P. Ceppa, and F. Botta Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C Am J Gastroenterol 95 2000 3211 3217
47. M. Romero-Gomez, V.M. Castellano-Megias, and L. Grande Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C Am J Gastroenterol 98 2003 1135 1141
48. J. Crespo, M. Rivero, and E. Fabrega Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis Dig Dis Sci 47 2002 1604 1610
49. T. Piche, F. Vandenbos, and A. Abakar-Mahamat The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C J Viral Hepat 11 2004 91 96
50. G. Perlemuter, A. Sabile, and P. Letteron Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis FASEB J 16 2002 185 194
51. A.I. Su, J.P. Pezacki, and L. Wodicka Genomic analysis of the host response to hepatitis C virus infection Proc Natl Acad Sci U S A 99 2002 15669 15674
52. M.S. Brown, and J.L. Goldstein The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor Cell 89 1997 331 340
53. J. Ye, C. Wang, and R. Sumpter Jr Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation Proc Natl Acad Sci U S A 100 2003 15865 15870
54. L. Serfaty, T. Andreani, and P. Giral Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C J Hepatol 34 2001 428 434
55. J.M. Petit, M. Benichou, and L. Duvillard Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis Am J Gastroenterol 98 2003 1150 1154
56. V. Agnello, G. Abel, and M. Elfahal Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor Proc Natl Acad Sci U S A 96 1999 12766 12771
57. G. Barba, F. Harper, and T. Harada Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets Proc Natl Acad Sci U S A 94 1997 1200 1205
58. S.T. Shi, S.J. Polyak, and H. Tu Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins Virology 292 2002 198 210
59. R.G. Hope, and J. McLauchlan Sequence motifs required for lipid droplet association and protein stability are unique to the hepatitis C virus core protein J Gen Virol 81 2000 1913 1925
60. H. Lerat, M. Honda, and M.R. Beard Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus Gastroenterology 122 2002 352 365
61. M. Okuda, K. Li, and M.R. Beard Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein Gastroenterology 122 2002 366 375
62. H. Fujie, H. Yotsuyanagi, and K. Moriya Steatosis and intrahepatic hepatitis C virus in chronic hepatitis J Med Virol 59 1999 141 145
63. L. Rubbia-Brandt, R. Quadri, and K. Abid Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3 J Hepatol 33 2000 106 115
64. C. Hezode, F. Roudot-Thoraval, and E.-S. Zafrani Different mechanisms of steatosis in hepatitis C virus genotypes I and 3 infections J Viral Hep 11 2004 455 458
65. L. Castera, C. Hezode, and F. Roudot-Thoraval Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatoisis Gut 53 2004 420 424
66. P. Angulo Nonalcoholic fatty liver disease N Engl J Med 346 2002 1221 1231
67. S.A. Harrison, and B.A. Neuschwander-Tetri Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis Clin Liver Dis 8 2004 861 879
68. B.A. Neuschwander-Tetri, E.M. Brunt, and K.R. Wehmeier Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone Hepatology 38 2003 1008 1017
69. K. Promrat, G. Lutchman, and G.I. Uwaifo A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis Hepatology 39 2004 188 196